July 31 (Reuters) - Antibe Therapeutics Inc ATE.V :
* ANTIBE THERAPEUTICS PROVIDES CLINICAL DEVELOPMENT UPDATE ON ITS LEAD DRUG
* ANTIBE THERAPEUTICS - ATB-346 PHASE 2 DOSE-RANGING, EFFICACY STUDY REMAINS ON TRACK TO COMMENCE THIS QUARTER
* ANTIBE - RECENTLY COMPLETED SERIES OF ANIMAL METABOLISM STUDIES THAT PROVIDED KEY INSIGHTS ON PHARMACOKINETIC PROFILE OF ATB-346
* ANTIBE THERAPEUTICS INC - INSIGHTS CAN BE LEVERAGED TO BETTER DETERMINE DOSES, DOSING REGIMENS FOR UPCOMING ATB-346 PHASE 2 STUDY
* ANTIBE - ESTIMATES FULL ATB-346 PHASE 2 STUDY TO COST ABOUT $3 MILLION; TO BE FUNDED WITH CASH ON HAND
* ANTIBE THERAPEUTICS - TOP-LINE DATA READ-OUT FROM ATB-346 PHASE 2 STUDY ANTICIPATED IN Q2 2019